DrugPatentWatch Database Preview
Alpharma Company Profile
» See Plans and Pricing
What is the competitive landscape for ALPHARMA, and when can generic versions of ALPHARMA drugs launch?
ALPHARMA has sixty-three approved drugs.
There are nine US patents protecting ALPHARMA drugs.
There are fifty-five patent family members on ALPHARMA drugs in twenty-three countries and seven supplementary protection certificates in three countries.
Summary for Alpharma
| International Patents: | 55 |
| US Patents: | 9 |
| Tradenames: | 45 |
| Ingredients: | 42 |
| NDAs: | 63 |
Drugs and US Patents for Alpharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpharma Us Pharms | NYSTATIN | nystatin | SUSPENSION;ORAL | 062571-001 | Oct 29, 1985 | DISCN | No | No | Start Trial | Start Trial | |||||
| Alpharma Us Pharms | SERAX | oxazepam | TABLET;ORAL | 015539-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-001 | Aug 13, 2009 | DISCN | Yes | No | 7,682,634 | Start Trial | Y | Start Trial | |||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-006 | Aug 13, 2009 | DISCN | Yes | No | 8,685,444 | Start Trial | Y | Start Trial | |||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-004 | Aug 13, 2009 | DISCN | Yes | No | 8,685,444 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alpharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-003 | Aug 13, 2009 | 5,202,128 | Start Trial |
| Alpharma Us Pharms | SERAX | oxazepam | CAPSULE;ORAL | 015539-004 | Approved Prior to Jan 1, 1982 | 4,620,974 | Start Trial |
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-006 | Aug 13, 2009 | 5,378,474 | Start Trial |
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-001 | Aug 13, 2009 | 5,202,128 | Start Trial |
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-004 | Aug 13, 2009 | 5,378,474 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALPHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mg | ➤ Subscribe | 2010-05-28 |
| ➤ Subscribe | Extended-release Capsules | 100 mg/4 mg | ➤ Subscribe | 2010-05-03 |
| ➤ Subscribe | Extended-release Capsules | 60 mg/2.4 mg | ➤ Subscribe | 2010-05-25 |
International Patents for Alpharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 20051855 | Start Trial |
| European Patent Office | 1551372 | Start Trial |
| Brazil | PI0714039 | Start Trial |
| Portugal | 2719378 | Start Trial |
| European Patent Office | 2422773 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alpharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1581193 | SPC/GB12/047 | United Kingdom | Start Trial | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 0809498 | SPC/GB10/012 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 1429780 | 13C0012 | France | Start Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| 0809498 | 10C0038 | France | Start Trial | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 2233112 | 132014902285293 | Italy | Start Trial | PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
